Werewolf Therapeutics, Inc.
HOWLNasdaq
$0.37
↑ +0.0%Jul 17 close · end-of-day
Price
1Y↓ -72.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$18.2M
Enterprise Value
$3.8M
P/E
—
P/S
—
P/B
1.5
EV/EBITDA
—
PEG
—
FCF Yield
-331.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$56.3M
Free Cash Flow (TTM)
-$60.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-461.1%
ROIC
—
Debt / Equity
2.6
Net Cash
$14.4M
Return 1Y
-73.7%
Company profile
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
- CEO
- Daniel J. Hicklin
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- Massachusetts
- Website
- werewolftx.com
Earnings
HOWL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.28↓ -30.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$22.4M | -$50.1M | -$56.1M | -$40.5M | -$73.6M | -$60.7M |
| Net income | -$15.0M | -$50.0M | -$53.8M | -$37.4M | -$70.5M | -$60.8M |
| Diluted EPS | -$28.08 | -$10.94 | -$1.86 | -$1.05 | -$1.63 | -$1.33 |
| Operating cash flow | -$18.6M | -$42.9M | -$40.6M | -$32.6M | -$56.2M | -$60.3M |
| Free cash flow | -$19.2M | -$43.4M | -$44.2M | -$33.4M | -$56.4M | -$60.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$19.0M | -$17.1M | -$20.3M | -$18.0M | -$17.5M | -$15.7M | -$9.4M | -$13.3M |
| Net income | -$17.2M | -$16.7M | -$20.4M | -$18.1M | -$18.0M | -$16.4M | -$8.4M | -$13.5M |
| Diluted EPS | -$0.43 | -$0.38 | -$0.43 | -$0.40 | -$0.40 | -$0.36 | -$0.17 | -$0.28 |
| Operating cash flow | -$14.2M | -$12.5M | -$14.3M | -$18.9M | -$15.2M | -$15.2M | -$11.0M | -$10.6M |
| Free cash flow | -$14.2M | -$12.5M | -$14.4M | -$18.9M | -$15.2M | -$15.2M | -$11.0M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Feb 24, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | EVNIN LUKE | Sale | 107,429 | $0.31 | $33,302.99 | filing |
| 2026-07-06 | EVNIN LUKE | Sale | 35,770 | $0.32 | $11,446.40 | filing |
| 2026-06-29 | EVNIN LUKE | Sale | 157,084 | $0.30 | $47,125.20 | filing |
| 2026-06-17 | RA CAPITAL MANAGEMENT, LLC | Sale | 389,216 | $0.35 | $136,225.60 | filing |
| 2026-06-17 | RA CAPITAL MANAGEMENT, LLC | Sale | 27,695 | $0.35 | $9,693.25 | filing |
| 2026-06-16 | RA CAPITAL MANAGEMENT, LLC | Sale | 139,686 | $0.37 | $51,683.82 | filing |
| 2026-06-16 | RA CAPITAL MANAGEMENT, LLC | Sale | 9,939 | $0.37 | $3,677.43 | filing |
| 2026-06-15 | RA CAPITAL MANAGEMENT, LLC | Sale | 120,216 | $0.39 | $46,884.24 | filing |
| 2026-06-15 | RA CAPITAL MANAGEMENT, LLC | Sale | 8,554 | $0.39 | $3,336.06 | filing |
| 2026-06-12 | RA CAPITAL MANAGEMENT, LLC | Sale | 159,119 | $0.40 | $63,647.60 | filing |
| 2026-06-12 | RA CAPITAL MANAGEMENT, LLC | Sale | 11,322 | $0.40 | $4,528.80 | filing |
| 2026-06-11 | RA CAPITAL MANAGEMENT, LLC | Sale | 245,066 | $0.38 | $93,125.08 | filing |
| 2026-06-11 | RA CAPITAL MANAGEMENT, LLC | Sale | 17,437 | $0.38 | $6,626.06 | filing |
| 2026-06-10 | RA CAPITAL MANAGEMENT, LLC | Sale | 42,872 | $0.37 | $15,862.64 | filing |
| 2026-06-10 | RA CAPITAL MANAGEMENT, LLC | Sale | 3,051 | $0.37 | $1,128.87 | filing |
| 2026-06-09 | RA CAPITAL MANAGEMENT, LLC | Sale | 345,235 | $0.37 | $127,736.95 | filing |
| 2026-06-09 | EVNIN LUKE | Sale | 76,928 | $0.37 | $28,463.36 | filing |
| 2026-06-09 | RA CAPITAL MANAGEMENT, LLC | Sale | 24,565 | $0.37 | $9,089.05 | filing |
| 2026-06-08 | EVNIN LUKE | Sale | 60,547 | $0.40 | $24,218.80 | filing |
| 2026-06-05 | EVNIN LUKE | Sale | 24,946 | $0.40 | $9,978.40 | filing |
| 2026-06-04 | EVNIN LUKE | Sale | 20,072 | $0.44 | $8,831.68 | filing |
| 2026-06-03 | EVNIN LUKE | Sale | 29,749 | $0.42 | $12,494.58 | filing |
| 2026-06-02 | EVNIN LUKE | Sale | 29,595 | $0.45 | $13,317.75 | filing |
| 2026-06-01 | EVNIN LUKE | Sale | 80,459 | $0.47 | $37,815.73 | filing |
| 2026-05-29 | EVNIN LUKE | Sale | 32,556 | $0.45 | $14,650.20 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.